Blue Bird (NASDAQ:BLBD) Hits New 1-Year High – Should You Buy?

Chronological Source Flow
Back

AI Fusion Summary

Blue Bird shares hit a 52‑week high, trading up to $65.47. Needham and Barclays raised targets; Zen downgraded to buy. Relay Therapeutics reached a 52‑week high of $15.89. Wells Fargo raised objectives; Weiss Ratings issued a sell (d‑) rating.
#BLUE_BIRD #RELAY_THERAPEUTICS #STOCK_MARKET #ANALYST_UPGRADE #SELL_RATING
15/04 09:32 defenseworld.net
3 Πηγές

Blue Bird (NASDAQ:BLBD) Hits New 1-Year High – Should You Buy?

COMPANIESPOLITICSPRICE ARTICLES
15/04 09:38 defenseworld.net

Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year High – Should You Buy?

EARTHQUAKEPRICE ARTICLESPOLITICSCOMPANIES
15/04 10:09 defenseworld.net

Revolution Medicines (NASDAQ:RVMD) Hits New 1-Year High – Should You Buy?

COMPANIESPRICE ARTICLESPOLITICS
Comments
Loading...
0